Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial conditions during the Class Period from April 18, 2024, to October 16, 2024 [1][2]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Allegations and Financial Impact - The lawsuit claims that Elevance misled investors about its monitoring of cost trends related to the Medicaid "redetermination" process, assuring them that premium rates were sufficient despite rising Medicaid expenses [4]. - The redetermination process led to a significant increase in the utilization of Medicaid members, as healthier members were being removed from the program, which was not reflected in Elevance's financial guidance or rate negotiations [5]. - On July 17, 2024, Elevance disclosed an expected increase in Medicaid utilization, resulting in a stock price drop of $32.21 per share, or 5.8%, closing at $520.93 [6]. - On October 17, 2024, Elevance reported Q3 2024 earnings, missing EPS expectations by $1.33, or 13.7%, and lowered its EPS guidance for 2024 from $37.20 to $33.00, or 11.3%, due to ongoing Medicaid issues [7]. - Following this announcement, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [8].

Core Viewpoint - A class action lawsuit has been filed against Elevance Health, Inc. for allegedly failing to disclose the impact of Medicaid redetermination on its business prospects, leading to significant financial misrepresentation [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Elevance Health misled investors by stating that they were monitoring Medicaid cost trends and that premium rates were sufficient to manage risks, despite rising Medicaid expenses [2]. - The company allegedly failed to disclose that the Medicaid redetermination process was resulting in a higher acuity and utilization of its Medicaid members, which was not reflected in their financial guidance for 2024 [2]. - Following the revelation of increased utilization expectations in the Medicaid sector, Elevance's stock price dropped by $32.21 per share, or 5.8%, indicating a significant market reaction to the disclosed information [3]. Group 2: Legal Proceedings - Shareholders interested in participating in the class action must file their papers by July 11, 2025, to serve as lead plaintiff, representing the interests of other class members [4]. - Shareholders are not required to participate in the case to be eligible for recovery, allowing them to remain absent class members if they choose [4]. Group 3: Company Background - Robbins LLP, the law firm handling the case, has been focused on shareholder rights litigation since 2002, aiming to help shareholders recover losses and improve corporate governance [5].

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Investors have until July 11, 2025, to ask the Court to be appointed to ...

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may have until July 11, 2025, to request to lead the case [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused Medicaid eligibility reviews during COVID-19, which resumed in 2023, leading to increased acuity and utilization among Elevance's Medicaid members [3][5]. Group 3: Financial Impact and Stock Performance - Elevance had previously stated it was monitoring cost trends related to Medicaid redetermination, claiming that negotiated rates were sufficient [4]. - Following the announcement of increased utilization in Medicaid on July 17, 2024, Elevance's stock price fell by $32.21, nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing EPS expectations by $1.33 (13.7%) due to elevated medical costs, resulting in a stock price decline of $52.61, nearly 11%, from $496.96 to $444.35 per share [7].

Core Viewpoint - UnitedHealth Group and Elevance Health are two leading healthcare plan providers in the U.S., both recognized for their scale, diversified offerings, and solid financial performance, making them attractive defensive investments in volatile markets [1][2]. Group 1: UnitedHealth Group (UNH) - UnitedHealth is a dominant player in the industry, benefiting from its extensive scale and operational efficiency through its Optum unit, which supports its resilience against macroeconomic pressures [3]. - The company has faced significant challenges, with its market cap dropping from $566.7 billion in November 2024 to $269.1 billion currently, alongside missing earnings and revenue estimates due to lower premiums and high medical costs [4]. - A leadership change has occurred, with CEO Andrew Witty stepping down and former CEO Stephen Hemsley returning, amidst a criminal investigation related to potential Medicare fraud, raising investor concerns [5]. - Despite these challenges, UnitedHealth's diversification across various insurance segments and consistent free cash flow provide a buffer against sector-specific risks, with a dividend yield of 2.83% [6]. Group 2: Elevance Health (ELV) - Elevance Health, while smaller, is demonstrating stronger operational momentum, particularly in government-backed plans like Medicaid and Medicare Advantage [7]. - The company outperformed estimates in its latest quarterly report, with a 14.5% year-over-year increase in premiums to $40.9 billion, and improved operating expense ratio of 10.9% compared to UNH's 12.4% [8][9]. - Elevance's long-term debt to capital ratio of 39.7% is lower than UnitedHealth's 42.7%, indicating less leverage and lower vulnerability to high-interest rates [10]. Group 3: Comparative Analysis - Zacks Consensus Estimates currently favor Elevance, with upward revisions in EPS estimates for the current year, while UnitedHealth has seen multiple downward revisions [11]. - In terms of valuation, Elevance trades at a forward P/E of 10.60, compared to UnitedHealth's 11.76, suggesting a more attractive risk-reward profile for Elevance [12]. - Year-to-date, Elevance shares have gained 4.2%, outperforming both the industry and S&P 500, while UnitedHealth shares have declined by 41.4% due to concerns over medical costs and investigations [14]. Conclusion - Both companies are established players in the healthcare sector, with UnitedHealth offering scale and diversification but facing short-term challenges, while Elevance shows stronger execution and a more favorable growth narrative [16]. - Elevance Health is positioned as the more promising investment opportunity currently, supported by better valuation, earnings revisions, and price performance [17].

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Investors have until July 11, 2025, to ask the Court to be appointed to ...

Core Viewpoint - A class action lawsuit has been filed against Elevance Health, Inc. for allegedly failing to disclose the impact of Medicaid redetermination on its business prospects, leading to significant financial misrepresentation during the class period from April 18, 2024, to October 16, 2024 [1][2]. Group 1: Allegations and Financial Impact - The complaint alleges that Elevance Health misled investors by claiming they were monitoring cost trends related to Medicaid redetermination and that premium rates were sufficient to manage associated risks, despite rising Medicaid expenses [2]. - The company assured investors that the acuity mix shift in its Medicaid business was within expected bounds, while in reality, the redetermination process resulted in a higher number of sicker patients remaining on Medicaid, leading to increased per-patient costs not reflected in financial guidance [2]. - On July 17, 2024, Elevance disclosed an expectation of increased utilization in Medicaid, which caused its stock price to drop by $32.21 per share, or 5.8%, from $553.14 to $520.93 [3]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers by July 11, 2025, although participation is not required to be eligible for recovery [4]. - The law firm Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5].

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Elevance Health, Inc. (NYSE: ELV) between April 18, 2024 and October 16, 2024, both dates inclusive (the “Class Period”), of the important July 11, 2025 lead plaintiff deadline. SO WHAT: If you purchased Elevance common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

Core Insights - The article highlights the 28th annual list of the world's most influential businesswomen, emphasizing the increasing competition as more women lead significant companies. The ranking is data-driven, utilizing a complex scoring system that considers various dimensions beyond just company size and performance [1][2]. Group 1: Rankings and Notable Leaders - The top three positions are held by Mary Barra (CEO of General Motors), Julie Sweet (CEO of Accenture), and Jane Fraser (CEO of Citigroup) [1][2]. - The list includes leaders from various global companies, with notable mentions from Walmart and Netflix [1]. Group 2: Geographic Representation - Over half of the women on the list work in the United States, with significant representation from China (10), France (7), the UK (7), and Brazil (3) [2]. - The Chinese representatives include notable figures such as Meng Wanzhou (Huawei), Joey Wat (Yum China), and others from leading companies [2]. Group 3: Emerging Leaders - Among the 16 new entrants, several have returned to the list after years, including Michelle Gass (CEO of Levi's) and Claudine Adamo (Chief Procurement Officer at Costco) [2]. - The list reflects a mix of seasoned executives and rising stars, indicating a dynamic shift in leadership [2]. Group 4: Business Performance and Challenges - General Motors, under Mary Barra, achieved record revenue in 2024, with a 9% year-over-year increase, and doubled its market share in electric vehicles [6]. - Citigroup, led by Jane Fraser, reported a net profit increase from $9.2 billion in 2023 to $12.7 billion in 2024, prompting a $20 billion stock buyback plan [10]. - Accenture, under Julie Sweet, demonstrated agility by hosting webinars for 900 clients in response to new tariffs, showcasing the ability to adapt quickly to market changes [7]. Group 5: Industry Trends and Innovations - The article notes a shift in evaluating business influence, with a diminishing absolute reliance on company size, as seen with Mira Murati of Thinking Machines Lab, who leads a seed-stage company [3]. - The focus on technology and innovation is evident, with leaders like Safra Catz of Oracle and Lisa Su of AMD navigating challenges in the tech sector while pushing for advancements in AI [11][42].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for the period between April 18, 2024, and October 16, 2024, due to financial disclosures that negatively impacted the company's stock price [1][5]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Financial Disclosures - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization, leading to a stock price decline of $32.21 per share, or 5.8%, closing at $520.93 [4]. - On October 17, 2024, Elevance reported Q3 2024 financial results, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business. The company also lowered its EPS guidance for 2024 from $37.20 to $33.00, or 11.3% [5]. - Following the October announcement, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [6].